beyond alpha glp 1 reviews The expanding benefits of GLP-1 medicines: Cell Reports Medicine Current Insights, Advantages and Challenges
Description
Daubert motions due April 1 as bellwether trials approach for 2027
Abstract Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough therapies for type 2 diabetes mellitus (T2DM)
Some providers may prescribe off-label for specific metabolic conditions, but this remains controversial and is not covered by any standard insurance plan
However, this data comes from observational studies, not randomized controlled trials, so it should be interpreted cautiously
PloS One 7, e35240
